Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors
- 14 May 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (17), 4633-4642
- https://doi.org/10.1158/1078-0432.CCR-19-3498
Abstract
Purpose: The purpose of this study was to evaluate the rational combination of TORC1/2 inhibitor TAK-228 and Aurora A kinase inhibitor alisertib in preclinical models of triple-negative breast cancer (TNBC) and to conduct a phase I dose escalation trial in patients with advanced solid tumors. Experimental Design: TNBC cell lines and patient-derived xenograft (PDX) models were treated with alisertib, TAK-228, or the combination and evaluated for changes in proliferation, cell cycle, mTOR pathway modulation, and terminal cellular fate, including apoptosis and senescence. A phase I clinical trial was conducted in patients with advanced solid tumors treated with escalating doses of alisertib and TAK-228 using a 3+3 design to determine the maximum tolerated dose (MTD). Results: The combination of TAK-228 and alisertib resulted in decreased proliferation and cell-cycle arrest in TNBC cell lines. Treatment of TNBC PDX models resulted in significant tumor growth inhibition and increased apoptosis with the combination. In the phase I dose escalation study, 18 patients with refractory solid tumors were enrolled. The MTD was alisertib 30 mg b. i.d. days 1 to 7 of a 21-day cycle and TAK-2282 mg daily, continuous dosing. The most common treatment-related adverse events were neutropenia, fatigue, nausea, rash, mucositis, and alopecia. Conclusions: The addition of TAK-228 to alisertib potentiates the antitumor activity of alisertib in vivo, resulting in increased cell death and apoptosis. The combination is tolerable in patients with advanced solid tumors and should be evaluated further in expansion cohorts with additional pharmacodynamic assessment.Other Versions
Funding Information
- CTEP MTA (15-2-00025)
- CPRIT (RR160093)
This publication has 42 references indexed in Scilit:
- Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid TumorsClinical Cancer Research, 2012
- p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast CancerCancer Cell, 2012
- Aurora kinase inhibitors: Progress towards the clinicInvestigational New Drugs, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerThe New England Journal of Medicine, 2012
- Apoptosis, autophagy, accelerated senescence and reactive oxygen in the response of human breast tumor cells to AdriamycinBiochemical Pharmacology, 2009
- Visualizing Spatiotemporal Dynamics of Multicellular Cell-Cycle ProgressionCell, 2008
- Cellular senescence: when bad things happen to good cellsNature Reviews Molecular Cell Biology, 2007
- Evasion of a Single-Step, Chemotherapy-Induced Senescence in Breast Cancer Cells: Implications for Treatment ResponseClinical Cancer Research, 2005
- Aurora-A Abrogation of p53 DNA Binding and Transactivation Activity by Phosphorylation of Serine 215Journal of Biological Chemistry, 2004
- Identification and Functional Characterization of Lsm Proteins in Trypanosoma bruceiOnline Journal of Public Health Informatics, 2004